本帖最后由 老马 于 2012-1-13 21:20 编辑
. P1 m) V. C Q# k% ^" |$ G4 D
4 }% z; L) G7 d+ _爱必妥和阿瓦斯丁的比较0 @' _8 D& Y' c9 |) _# s
+ Z1 ?5 O0 d M+ x, Q
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/# F4 x$ \6 [$ _/ w. B
' x6 W+ E6 g" Y* v; s: E
: W( L3 n& D1 _6 M0 y5 p# K1 {
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/$ p: u6 F0 \8 Y; \. C
==================================================$ x, i' F _) `9 z$ |: ?6 a
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)' P- w( h/ ?; X+ ^! I. B
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
& Z/ R' |9 m/ |Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
# A! e* ~3 x. {$ _4 C
|